Apollo-backed dental firm vVardis seeks up to $229 million in US IPO

vVardis is seeking to raise up to $228.6 million in a NYSE IPO at a fully diluted valuation of about $4.4 billion at the top of its $21–$24 per-share range. For the nine months ended September 30, 2026, preliminary revenue is projected at $47.7–$49.2 million, more than double the year-earlier $22.3 million, with gross margin near 86% and Adjusted EBITDA loss narrowing to $9.2–$9.4 million from $17.1 million. Net loss is expected to remain broadly stable at $39.7–$41.3 million; the co-founders will retain 87.0% of voting power after the offering.

Analysis

The key underwriting question is whether early adoption converts into repeat use across the installed base—not whether initial clinic placement can keep growing. The reported practice count says little about treatment frequency per office, patient conversion, or reorder rates; those are the best near-term checks on whether the revenue trajectory can support a premium valuation. At the proposed fully diluted value, annualizing the nine-month revenue range implies roughly 67–69x sales, a demanding multiple even with strong gross margins. Operating leverage is not yet proven: adjusted EBITDA losses narrowed, while net losses remained substantial.

The exclusive Henry Schein (HSIC) channel can accelerate access, but also creates distribution dependence; the incremental economics for HSIC are unquantified and likely too small to underwrite a material earnings change without evidence of meaningful product contribution. Longer term, successful adoption could shift some early-lesion treatment toward minimally invasive care, but dentist workflow and patient conversion—not just product availability—will determine whether that expands the market or substitutes for existing procedures.

Governance and float are meaningful risks: founder voting control limits outside influence, while the overallotment shares come from founders rather than funding the company. That can constrain liquidity and amplify post-listing price swings. The contrarian upside is that the market may underwrite a preventive-care platform rather than a single product; the counterpoint is that platform expansion is not established by the supplied data. Reassess after the IPO using reorder trends, revenue per active practice, cash burn, and any evidence of broader product adoption.

Key Decisions for Investors

• Avoid chasing the IPO at the top of the range; treat the implied sales multiple as pricing in sustained high growth and successful conversion from clinic placement to recurring use. Revisit after initial trading and the first public operating update.
• Set an alert for vVardis (proposed ticker VVVV) on quarterly revenue per active practice, reorder rates, and operating cash burn. Weakening repeat demand or renewed widening in adjusted EBITDA losses would falsify the adoption-and-leverage thesis.
• Keep Henry Schein (HSIC) on watch, not as a direct event trade: the distribution relationship may support its dental channel, but the article provides no product-level sales or profit contribution to establish material earnings sensitivity.
• Account for controlled-company governance and potentially limited float in sizing any post-listing position; avoid using a short as a valuation expression until borrow availability and trading liquidity are observable.